Pharvaris (PHVS) has released an update.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Pharvaris, a biopharmaceutical company, has showcased promising data at the Bradykinin Symposium 2024 for their oral drug candidate deucrictibant, aimed at preventing and treating hereditary angioedema (HAE). The presented studies demonstrate deucrictibant’s long-term safety and efficacy, including significant reductions in attack occurrence and improvements in patient quality of life. This supports the potential of deucrictibant as a novel oral prophylactic and on-demand therapy for HAE.
For further insights into PHVS stock, check out TipRanks’ Stock Analysis page.
